Literature DB >> 17613531

Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE.

Hookang Im1, Marika Manolopoulou, Enrico Malito, Yuequan Shen, Ji Zhao, Marie Neant-Fery, Ching-Yu Sun, Stephen C Meredith, Sangram S Sisodia, Malcolm A Leissring, Wei-Jen Tang.   

Abstract

Insulin-degrading enzyme (IDE) is a zinc metalloprotease that hydrolyzes amyloid-beta (Abeta) and insulin, which are peptides associated with Alzheimer disease (AD) and diabetes, respectively. Our previous structural analysis of substrate-bound human 113-kDa IDE reveals that the N- and C-terminal domains of IDE, IDE-N and IDE-C, make substantial contact to form an enclosed catalytic chamber to entrap its substrates. Furthermore, IDE undergoes a switch between the closed and open conformations for catalysis. Here we report a substrate-free IDE structure in its closed conformation, revealing the molecular details of the active conformation of the catalytic site of IDE and new insights as to how the closed conformation of IDE may be kept in its resting, inactive conformation. We also show that Abeta is degraded more efficiently by IDE carrying destabilizing mutations at the interface of IDE-N and IDE-C (D426C and K899C), resulting in an increase in Vmax with only minimal changes to Km. Because ATP is known to activate the ability of IDE to degrade short peptides, we investigated the interaction between ATP and activating mutations. We found that these mutations rendered IDE less sensitive to ATP activation, suggesting that ATP might facilitate the transition from the closed state to the open conformation. Consistent with this notion, we found that ATP induced an increase in hydrodynamic radius, a shift in electrophoretic mobility, and changes in secondary structure. Together, our results highlight the importance of the closed conformation for regulating the activity of IDE and provide new molecular details that will facilitate the development of activators and inhibitors of IDE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17613531     DOI: 10.1074/jbc.M701590200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  Ubiquitin is a novel substrate for human insulin-degrading enzyme.

Authors:  Luis A Ralat; Vasilios Kalas; Zhongzhou Zheng; Robert D Goldman; Tobin R Sosnick; Wei-Jen Tang
Journal:  J Mol Biol       Date:  2010-12-23       Impact factor: 5.469

Review 2.  Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.

Authors:  Wei-Jen Tang
Journal:  Trends Endocrinol Metab       Date:  2015-12-02       Impact factor: 12.015

Review 3.  Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin.

Authors:  E Malito; R E Hulse; W-J Tang
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

4.  Yeast Ste23p shares functional similarities with mammalian insulin-degrading enzymes.

Authors:  Benjamin J Alper; Jarrad W Rowse; Walter K Schmidt
Journal:  Yeast       Date:  2009-11       Impact factor: 3.239

5.  Potential efficacy of Lactobacillus casei IBRC_M10711 on expression and activity of insulin degrading enzyme but not insulin degradation.

Authors:  Nadia Neyazi; Taiebeh Mohammadi Farsani; Zahra Nouri; Mohammad Hossein Ghahremani; Mohammad Reza Khorramizadeh; Roksana Tajerian; Elahe Motevaseli
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-08-29       Impact factor: 2.416

6.  Structure-activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme.

Authors:  Julie Charton; Marion Gauriot; Jane Totobenazara; Nathalie Hennuyer; Julie Dumont; Damien Bosc; Xavier Marechal; Jamal Elbakali; Adrien Herledan; Xiaoan Wen; Cyril Ronco; Helene Gras-Masse; Antoine Heninot; Virginie Pottiez; Valerie Landry; Bart Staels; Wenguang G Liang; Florence Leroux; Wei-Jen Tang; Benoit Deprez; Rebecca Deprez-Poulain
Journal:  Eur J Med Chem       Date:  2014-12-04       Impact factor: 6.514

7.  Molecular basis of substrate recognition and degradation by human presequence protease.

Authors:  John V King; Wenguang G Liang; Kathryn P Scherpelz; Alexander B Schilling; Stephen C Meredith; Wei-Jen Tang
Journal:  Structure       Date:  2014-06-12       Impact factor: 5.006

8.  Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme.

Authors:  Enrico Malito; Luis A Ralat; Marika Manolopoulou; Julie L Tsay; Natasha L Wadlington; Wei-Jen Tang
Journal:  Biochemistry       Date:  2008-12-02       Impact factor: 3.162

9.  Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin.

Authors:  Malcolm A Leissring; Enrico Malito; Sabrine Hedouin; Lael Reinstatler; Tomoko Sahara; Samer O Abdul-Hay; Shakeel Choudhry; Ghulam M Maharvi; Abdul H Fauq; Malwina Huzarska; Philip S May; Sungwoon Choi; Todd P Logan; Benjamin E Turk; Lewis C Cantley; Marika Manolopoulou; Wei-Jen Tang; Ross L Stein; Gregory D Cuny; Dennis J Selkoe
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

10.  Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening.

Authors:  Christelle Cabrol; Malwina A Huzarska; Christopher Dinolfo; Maria C Rodriguez; Lael Reinstatler; Jake Ni; Li-An Yeh; Gregory D Cuny; Ross L Stein; Dennis J Selkoe; Malcolm A Leissring
Journal:  PLoS One       Date:  2009-04-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.